Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
Context Therapeutics Inc. (Nasdaq: CNTX) is a Philadelphia-based biopharmaceutical company dedicated to advancing innovative medicines for solid tumors. The company's core mission is to develop novel therapies for hormone-responsive cancers, with a particular focus on female cancers such as breast, ovarian, and endometrial cancer.
Context Therapeutics’ leading clinical candidate is CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody designed to target and engage T-cells in attacking CLDN6-positive tumors. Preclinical studies have shown promising results, with CTIM-76 demonstrating a capability to induce complete tumor regressions across multiple dose levels. The company plans to enroll the first patient in a Phase 1 clinical trial in mid-2024.
In addition to CTIM-76, Context Therapeutics is working on other promising programs, including Apristor (onapristone XR), an investigational drug targeting progesterone receptor-positive (PR+) breast cancer. Up to 70% of breast cancers express progesterone receptors, making Apristor a potential treatment option for a significant number of patients.
In recent news, Context Therapeutics announced encouraging financial results for the first quarter of 2024, including gross proceeds of approximately $100 million from a private placement. These funds are expected to support the company's operations and research endeavors well into 2028. The U.S. Food and Drug Administration (FDA) has also recently cleared Context's Investigational New Drug (IND) application for CTIM-76, a crucial step toward initiating clinical trials.
Context Therapeutics has a strong pipeline and strategic partnerships, including collaborations with Integral Molecular, which supports the development of therapies targeting difficult protein targets. The company’s robust financial guidance and innovative approach position it for significant growth in the biopharmaceutical sector.
Context Therapeutics (CNTX) reported Q3 2024 financial results and business updates. The company expanded its pipeline through acquisitions of CT-95 and CT-202, two T cell engaging bispecific antibodies. Cash position stood at $84.8 million as of September 30, 2024. Q3 net loss increased to $17.5 million from $5.9 million year-over-year, primarily due to R&D expenses of $16.8 million. The company expects current cash to fund operations into 2027, including Phase 1 trials for CTIM-76 and CT-95, and IND filing for CT-202.
Context Therapeutics (Nasdaq: CNTX), a biopharmaceutical company focused on T cell engagers for solid tumors, has announced its participation in three major investor conferences this November. The company will present at the Guggenheim Global Healthcare Conference (November 11), UBS Global Healthcare Conference (November 13), and Stifel 2024 Healthcare Conference (November 19).
The presentations will include fireside chats and one-on-one meetings with investors. All sessions will be webcast live and available for replay for 90 days on the company's investor relations website.
Context Therapeutics Inc. (Nasdaq: CNTX), a biopharmaceutical company focused on T cell engagers for solid tumors, has announced a poster presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting. The presentation will feature their clinical asset CTIM-76, a Claudin 6 x CD3 bispecific antibody.
The poster, titled 'Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6,' will be presented on Saturday, November 9, 2024, at 9:00 a.m. CDT in Exhibit Halls AB of the George R. Brown Convention Center in Houston, TX. The authors of the presentation are Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, and Eric Butz.
BioAtla and Context Therapeutics have entered into an exclusive worldwide license agreement for the development and commercialization of BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody. Key points include:
1. Context obtains exclusive rights to BA3362
2. BioAtla to receive $15.0 million in upfront and near-term milestones
3. Potential for up to $118.5 million in additional clinical, regulatory, and commercial milestones
4. BioAtla eligible for tiered royalties on net sales
5. Context anticipates IND filing for BA3362 in mid-2026
This agreement allows BioAtla to focus on its lead clinical CAB programs while advancing BA3362 under Context's leadership. Context views Nectin-4 as a priority target for solid tumors and sees BA3362 as a potentially best-in-class asset.
Context Therapeutics (Nasdaq: CNTX), a biopharmaceutical company focused on solid tumor treatments, has appointed Dr. Karen Smith and Dr. Luke Walker to its Board of Directors. Dr. Smith brings over 20 years of experience in drug development and commercialization, having contributed to successful products like Herceptin and Vyxeos. Dr. Walker offers extensive clinical development expertise, particularly in T cell engaging bispecific antibodies.
These appointments aim to support Context's growth and pipeline advancement. Dr. Smith's oncology drug development and regulatory experience, along with Dr. Walker's track record in oncology drug development, are expected to be valuable assets for the company's strategic goals.
Context Therapeutics (Nasdaq: CNTX) reported its Q2 2024 financial results and recent business highlights. Key points include:
- Acquisition of CT-95, a mesothelin x CD3 bispecific antibody
- Appointment of Dr. Claudio Dansky Ullmann as Chief Medical Officer
- Cash and cash equivalents of $101.5 million as of June 30, 2024
- FDA clearance for CTIM-76 IND, with first patient dosing expected in Q3 2024
- Closed a $100 million private placement in May 2024
- Net loss of $2.3 million for Q2 2024, compared to $5.0 million in Q2 2023
- Cash runway expected to fund operations into 2028
Context Therapeutics (Nasdaq: CNTX) has announced key appointments to support the development of its clinical-stage T cell engaging assets for solid tumors. Dr. Claudio Dansky Ullmann joins as Chief Medical Officer, bringing over 30 years of experience in oncology therapeutics development. Karen Andreas, M.S. is appointed as Vice President of Clinical Operations, with almost 20 years of biopharma experience.
These appointments come as Context advances its product candidates, CTIM-76 and CT-95, into Phase 1 clinical trials. The company is granting stock options to Dr. Dansky Ullmann and other new employees as inducement awards, subject to vesting conditions and Nasdaq listing rules.
Context Therapeutics, a biopharmaceutical company specializing in solid tumor treatments, has acquired CT-95, a potentially first-in-class mesothelin x CD3 bispecific antibody from Link Immunotherapeutics. This acquisition, announced on July 10, 2024, aligns with Context’s strategy to expand its pipeline of T cell engager assets. CT-95 has already received Investigational New Drug (IND) clearance from the U.S. FDA and is expected to begin Phase 1 trials in Q1 2025. The antibody targets mesothelin, prevalent in cancers like ovarian, lung, and pancreatic. Context plans to use its existing cash reserves to fund the acquisition and initial clinical trials.
Context Therapeutics Inc. reported on the FDA clearance of their IND application for a Phase 1 clinical trial of CTIM-76 and completed a $100 million financing round. They anticipate funding to last until 2028. The company showcased financial results for Q1 2024, emphasizing a decrease in R&D expenses and a net loss of $3.7 million for the quarter.
Context Therapeutics received FDA clearance for its IND application for a Phase 1 clinical trial of CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, focusing on gynecologic and testicular cancers. The Company aims to enroll the first patient by mid-2024.
FAQ
What is the current stock price of Context Therapeutics (CNTX)?
What is the market cap of Context Therapeutics (CNTX)?
What does Context Therapeutics Inc. do?
What is CTIM-76?
What types of cancer is Context Therapeutics targeting with their therapies?
What recent milestones has Context Therapeutics achieved?
When does Context Therapeutics plan to start the Phase 1 trial for CTIM-76?
What are the financial prospects for Context Therapeutics?
Who are some of Context Therapeutics' strategic partners?
What regulatory approvals has Context Therapeutics received recently?
Where is Context Therapeutics headquartered?
What is Apristor?
